CTRI/2024/03/063706
Recruiting
未知
Clinical Profile of Acute on Chronic Liver Failure and Chronic Liver Failure Consortium Acute on Chronic Liver Failure (CLIF C ACLF) score as a predictor of its short-term mortality - NI
Amar Minda0 sites0 target enrollmentStarted: TBDLast updated:
Overview
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Amar Minda
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
Inclusion Criteria
- •Patients of both genders aged more than 18 years with the diagnosis of ACLF according to the EASL CLIF definition.
Exclusion Criteria
- •1\. Previously diagnosed Hepatocellular carcinoma
- •2\. Have severe chronic extrahepatic disease
- •3\. Retro positive
- •4\. Patient on immunosuppressive drugs
- •5\. Acute CVA
- •6\. Acute MI
- •7\. Orthotopic liver transplantation during follow\-
- •8\. Pregnant females
- •9\. Those who are not willing to participate in the
Investigators
Similar Trials
Active, not recruiting
Phase 1
Biological mechanisms of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% in Subjects with cirrhosis with systemic inflammation and ACLFEUCTR2017-002677-19-ESInstituto Grifols S.A.250
Active, not recruiting
Phase 1
Biological mechanisms of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% in Subjects with cirrhosis with systemic inflammation and ACLFGroup 1 and 2:Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or duringhospitalization Group 3: Subject with cirrhosis hospitalized for Acute decompensation of cirrhosis (ascites, hepatic encephalopathy [HE], gastrointestinal hemorrhage, and/or bacterial infections)MedDRA version: 20.1Level: LLTClassification code 10064704Term: Decompensated cirrhosisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2017-002677-19-DEInstituto Grifols S.A.250
Active, not recruiting
Phase 1
Biological mechanisms of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% in Subjects with cirrhosis with systemic inflammation and ACLFGroup 1 and 2:Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization Group 3: Subject with cirrhosis hospitalized for Acute decompensation of cirrhosis (ascites, hepatic encephalopathy [HE], gastrointestinal hemorrhage, and/or bacterial infections)MedDRA version: 20.1Level: LLTClassification code 10064704Term: Decompensated cirrhosisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2017-002677-19-ITINSTITUTO GRIFOLS, S.A.
Active, not recruiting
Phase 1
Biological mechanisms of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% in Subjects with cirrhosis with systemic inflammation and ACLFEUCTR2017-002677-19-ATInstituto Grifols S.A.250
Active, not recruiting
Phase 1
Biological mechanisms of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% in Subjects with cirrhosis with systemic inflammation and ACLFGroup 1 and 2:Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or duringhospitalization Group 3: Subject with cirrhosis hospitalized for Acute decompensation of cirrhosis (ascites, hepatic encephalopathy [HE], gastrointestinal hemorrhage, and/or bacterial infections)MedDRA version: 20.1Level: LLTClassification code 10064704Term: Decompensated cirrhosisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2017-002677-19-BEInstituto Grifols S.A.250